293 related articles for article (PubMed ID: 36909335)
1. Obesity and myeloma: Clinical and mechanistic contributions to disease progression.
Marques-Mourlet C; Di Iorio R; Fairfield H; Reagan MR
Front Endocrinol (Lausanne); 2023; 14():1118691. PubMed ID: 36909335
[TBL] [Abstract][Full Text] [Related]
2. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
Gámez B; Edwards CM
Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
[TBL] [Abstract][Full Text] [Related]
3. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
Kristinsson SY; Björkholm M; Schulman S; Landgren O
Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma in the marrow: pathogenesis and treatments.
Fairfield H; Falank C; Avery L; Reagan MR
Ann N Y Acad Sci; 2016 Jan; 1364(1):32-51. PubMed ID: 27002787
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.
Zingone A; Kuehl WM
Semin Hematol; 2011 Jan; 48(1):4-12. PubMed ID: 21232653
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.
El-Masri BM; Leka B; Mustapha F; Gundesen MT; Hinge M; Lund T; Andersen TL; Diaz-delCastillo M; Jafari A
Oncotarget; 2024 Jan; 15():20-26. PubMed ID: 38227739
[TBL] [Abstract][Full Text] [Related]
9. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
Papachristou S; Popovic DS; Papanas N
Adv Ther; 2022 Jun; 39(6):2283-2286. PubMed ID: 35344184
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
11. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
13. Prevention of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV
Clin Cancer Res; 2009 Sep; 15(18):5606-8. PubMed ID: 19737944
[TBL] [Abstract][Full Text] [Related]
14. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
17. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Curr Hematol Malig Rep; 2010 Apr; 5(2):62-9. PubMed ID: 20425398
[TBL] [Abstract][Full Text] [Related]
19. Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
Hagos YB; Lecat CSY; Patel D; Mikolajczak A; Castillo SP; Lyon EJ; Foster K; Tran TA; Lee LSH; Rodriguez-Justo M; Yong KL; Yuan Y
Cancer Res; 2024 Feb; 84(3):493-508. PubMed ID: 37963212
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
